Pharmasia News

The pharma industry is on the edge of its seat with all eyes on the April 4 Group of Ministers (GoM) meeting which will decide on a final pricing policy for essential drugs, reports CNBC-TV18's Archana Shukla.

Biocon-Pfizer insulin deal might collapse soon: PharmAsia

The deal between Biocon and Pfizer to market a range of insulin products may be in crisis. Vikas Dandekar, the India Bureau Chief of PharmAsia News who broke this story tells CNBC-TV18 that while sources are saying talks are on to salvage the deal, it is most likely to be called off.

Ranbaxy's ANDA transfer saw Teva launch Lipitor: PharmAsia

The deal between pharma majors Ranbaxy and Teva, for the sale of generic version of the blockbuster cholesterol drug – Lipitor left many in the industry surprised. Vikas Dandekar, Bureau Chief, PharmAsia News tells CNBC-TV18 that the contours of the deal revolved around three scenarios at best.

Ranbaxy to find a new CFO

Ranbaxy CFO, Omesh Sethi has resigned. PharmAsia News India Bureau Chief, Vikas Dandekar, speaks exclusively to CNBC-TV18’s Reema Tendulkar on the exit and what it means for Ranbaxy.

Ranbaxy, Merck call off anti-infectives deal

Drug majors Ranbaxy and Merck have called off a deal that would have seen both the pharma giants join hands to research anti-infectives, reports PharmAsia News. The deal between the two companies was struck in 2008. Ranbaxy was to get milestones and an undisclosed upfront fee as part of the deal.